Future Fund LLC Buys 11,017 Shares of Penumbra, Inc. $PEN

Future Fund LLC increased its stake in shares of Penumbra, Inc. (NYSE:PEN) by 177.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,221 shares of the company’s stock after acquiring an additional 11,017 shares during the period. Penumbra comprises 1.9% of Future Fund LLC’s holdings, making the stock its 4th largest position. Future Fund LLC’s holdings in Penumbra were worth $5,354,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PEN. Larson Financial Group LLC grew its holdings in Penumbra by 4,100.0% during the fourth quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after acquiring an additional 82 shares during the period. Morse Asset Management Inc acquired a new stake in Penumbra during the fourth quarter worth about $39,000. Rothschild Investment LLC acquired a new stake in Penumbra during the third quarter worth about $40,000. Farther Finance Advisors LLC grew its holdings in Penumbra by 27.1% during the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock worth $55,000 after acquiring an additional 38 shares during the period. Finally, Allworth Financial LP grew its holdings in Penumbra by 36.2% during the third quarter. Allworth Financial LP now owns 241 shares of the company’s stock worth $61,000 after acquiring an additional 64 shares during the period. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Stock Down 0.2%

Shares of PEN opened at $318.46 on Friday. The company has a current ratio of 6.02, a quick ratio of 3.95 and a debt-to-equity ratio of 0.01. Penumbra, Inc. has a 12 month low of $221.26 and a 12 month high of $362.41. The stock’s 50 day moving average is $328.50 and its two-hundred day moving average is $324.56. The firm has a market cap of $12.53 billion, a P/E ratio of 73.38, a PEG ratio of 1.95 and a beta of 0.74.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). The firm had revenue of $374.76 million during the quarter, compared to analyst estimates of $370.47 million. Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The business’s revenue was up 15.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.83 earnings per share. Analysts predict that Penumbra, Inc. will post 5.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the company. UBS Group reaffirmed a “neutral” rating and set a $374.00 target price on shares of Penumbra in a report on Thursday, February 26th. Citigroup dropped their target price on Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a report on Thursday, May 7th. Evercore reaffirmed an “outperform” rating and set a $335.00 target price on shares of Penumbra in a report on Thursday, May 7th. Finally, Wall Street Zen raised Penumbra to a “hold” rating in a report on Saturday, May 9th. Three analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $361.33.

Insider Buying and Selling

In other news, Director Harpreet Grewal sold 100 shares of Penumbra stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $328.22, for a total value of $32,822.00. Following the sale, the director directly owned 8,719 shares of the company’s stock, valued at $2,861,750.18. The trade was a 1.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Maggie Yuen sold 2,432 shares of Penumbra stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $342.30, for a total value of $832,473.60. Following the completion of the sale, the chief financial officer directly owned 18,353 shares in the company, valued at $6,282,231.90. This represents a 11.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 2.90% of the company’s stock.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.